134 related articles for article (PubMed ID: 15609282)
1. Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy.
Malhotra P; Bhat P; Mahi S; Chauhan S; Rajwanshi A; Varma S
Am J Hematol; 2005 Jan; 78(1):82-3. PubMed ID: 15609282
[No Abstract] [Full Text] [Related]
2. [Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma].
Handa H; Irisawa H; Komatsumoto S; Matsushima T; Tsukamoto N; Nojima Y; Murakami H
Rinsho Ketsueki; 2006 Jun; 47(6):521-5. PubMed ID: 16862980
[TBL] [Abstract][Full Text] [Related]
3. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
4. Haematopoietic stem-cell transplantation in multiple myeloma.
Handelsman H
Cancer Treat Rev; 1996 Mar; 22(2):119-25. PubMed ID: 8665564
[No Abstract] [Full Text] [Related]
5. [Long-term fever and light-chain myeloma].
Gripenberg M
Duodecim; 1995; 111(4):345-7. PubMed ID: 8654302
[No Abstract] [Full Text] [Related]
6. Pleural and pericardial effusion as the first sign of multiple myeloma.
André M; Ponsonnaille J; Kemeny JL; Filaire M; Travade P; Aumaitre O
Ann Med Interne (Paris); 1999 Sep; 150(5):443-5. PubMed ID: 10544757
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Pönisch W; Niederwieser D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):23-6. PubMed ID: 12170429
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone.
Hrycek A; Gruszka A
Arch Med Res; 2006 Jan; 37(1):74-8. PubMed ID: 16314190
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy.
An SY; An CH; Choi KS; Heo MS
Dentomaxillofac Radiol; 2013; 42(4):20110143. PubMed ID: 23520399
[TBL] [Abstract][Full Text] [Related]
10. A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy.
Lazzaro A; Bernuzzi P; Arcari A; Bertè R; Moroni FC; Trabacchi E; Vallisa D; Cavanna L
Am J Hematol; 2006 Jul; 81(7):557. PubMed ID: 16755555
[No Abstract] [Full Text] [Related]
11. Urinary cytology in multiple myeloma.
Patil S; Schwarer A; McLean C
Cytopathology; 2008 Apr; 19(2):130-1. PubMed ID: 17488260
[No Abstract] [Full Text] [Related]
12. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous plasmacytomas following treatment of IgA kappa multiple myeloma].
Ortín X; Llorente A; Martínez S; Ugarriza A
Med Clin (Barc); 2004 Oct; 123(15):597-8. PubMed ID: 15535948
[No Abstract] [Full Text] [Related]
14. Optimising bortezomib in newly diagnosed multiple myeloma.
Rajkumar SV
Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
[No Abstract] [Full Text] [Related]
15. [Multiple myeloma and other plasma cell dyscrasias].
del Potro Gómez E; Morales Sanz D
Rev Clin Esp; 1999 Apr; 199 Suppl 1():52-7. PubMed ID: 10422451
[No Abstract] [Full Text] [Related]
16. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
[TBL] [Abstract][Full Text] [Related]
17. Dramatic response of diffuse osteosclerosis secondary to multiple myeloma using thalidomide with melphalan and prednisolone.
Mohamed M; Brain T; Khalafallah A
J Clin Oncol; 2014 Aug; 32(23):e85-7. PubMed ID: 24516032
[No Abstract] [Full Text] [Related]
18. A new standard of care for elderly patients with myeloma.
Palumbo A; Boccadoro M
Lancet; 2007 Oct; 370(9594):1191-2. PubMed ID: 17920906
[No Abstract] [Full Text] [Related]
19. [Plasmocytic pleural effusion disclosing multiple myeloma].
Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
[TBL] [Abstract][Full Text] [Related]
20. [Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].
Hoshino S; Saito H; Wada M; Akutsu M; Shiozaki H; Takanashi M; Takei Y; Tanaka S; Teramura M; Takada K
Rinsho Ketsueki; 1987 Mar; 28(3):358-65. PubMed ID: 3475485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
